Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL689616

CCCCC1CCC(C)CC1.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.58
HTT P42858 2/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NOS1 P29475 2/20 0.33
NOS2 P35228 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10881985 0.97 CYP1A2 (0.61) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL2901914 0.97 CYP1A2 (0.61) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL8219465 0.91 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10485824 0.91 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10485828 0.91 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10701936 0.91 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10974028 0.90 CYP1A2 (0.52) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL3293288 0.90 CYP1A2 (0.52) CYP1A2HTTMAPK1LMNAMAPT
Ammonia Solution, Strong SCHEMBL266627 0.89
Ammonia Solution, Strong SCHEMBL28122694 0.89 CYP1A2 (0.70) CYP1A2HTTMAPK1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
EP-1904438-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006761-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators GCK, HK1, GCKR CYP1A2 3207/4885HTT 1689/4885MAPK1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.